Eyenovia Inc. Announces Completion of Second Phase II Study 

NEW YORK--(BUSINESS WIRE)--Eyenovia Phase II study demonstrates its proprietary microtherapeutic approach can reduce ocular side effects with an 8% rate of ocular adverse events versus 66% for conventional topical treatment.